All news articles
-
NewsLilly advances neuroscience portfolio with $7.8bn acquisition of Centessa
Acquisition includes a potential best-in-class asset for excessive daytime sleepiness, broadening Lilly’s capabilities into sleep medicine.
-
NewsUCB’s TK2d therapy Kygevvi approved by European Commission
Authorisation of the small molecule therapy in the EU represents a new option for thymidine kinase 2 deficiency, builds on earlier US FDA approval.
-
NewsFramework supports microbiota assessment in cleanroom changing rooms
Case study presents a potential benchmarking model for microbial trend data and a data presentation format for pharmaceutical cleanrooms.
-
NewsHolistic automation for data integrity, usability and sustainability
IMA Active explores how interconnected, human-centric systems that implement advanced automation and usability can enhance operational efficiency and sustainability in tablet manufacturing.
-
NewsNovo Nordisk’s Awiqli first FDA-approved once-weekly basal insulin
The type 2 diabetes injection reduces administration frequency from daily to once per week, enhancing convenience for patients.
-
NewsMerck expands haematology pipeline with $6.7bn acquisition of Terns Pharmaceuticals
Deal strengthens Merck’s oncology portfolio with addition of a potential best-in-class oral TKI for chronic myeloid leukaemia.
-
NewsUCB positions new Georgia biologics facility as future US manufacturing hub
The biopharmaceutical company’s latest manufacturing venture represents one of the largest investments in Georgia’s history.
-
NewsAstraZeneca’s Imfinzi wins EU-first immunotherapy approval in early GI cancers
The approval represents the pharmaceutical company’s third perioperative approval in Europe for an Imfinzi-based regimen.
-
NewsGilead acquires potential first-in-class T cell engager in $2bn deal with Ouro Medicines
T cell engager gamgertamig could redefine standard of care for immune-mediated diseases.
-
NewsNanoparticle-exosome innovation could enhance cell therapy manufacturing
Novel, end-to-end process improves all four steps of exosome production simultaneously, supporting the design of more effective treatments.
-
NewsBMS wins dual immunotherapy-first approvals in classical Hodgkin Lymphoma
Expanded EU and US approvals for Bristol Myers Squibb’s Opdivo (nivolumab) position combination therapy as frontline option for the common blood cancer.
-
NewsNovartis strengthens its breast cancer pipeline with $3bn Synnovation acquisition
Deal to help address the significant unmet need in HR+/HER2- breast cancer and other advanced solid tumours.
-
NewsPennsylvania to house new actinium-225 manufacturing facility
Construction of TerraPower Isotopes’ cGMP facility increases its production capacity for the rare isotope, helping to boost global access to targeted alpha therapies.
-
NewsSandoz partners with Samsung Bioepis to accelerate biosimilar pipeline
New licensing, development and commercialisation agreement could expand Sandoz’s pipeline by to up to 32 assets.
-
NewsUpcycled plastic could facilitate production of Parkinson’s drug
Bioengineered E.coli provide an eco alternative to creating L-DOPA from terephthalic acid, suggests study.
-
NewsEli Lilly doubles down on supply chain investment in Asia
Pharma giant to strengthen manufacturing capabilities in Japan and add capacity in China for its first oral GLP-1 therapy candidate, orforglipron.
-
NewsSana's islet cell transplant therapy shows early promise in type 1 diabetes
Biotech company’s long-term data demonstrated hypoimmune (HIP)-modified islet transplantation without immunosuppression in type 1 diabetes.
-
NewsNeuro-specialist Lundbeck hires new AI lead
New recruit brings over 15 years of leadership experience to the brain health-focused biopharmaceutical company.
-
NewsChiesi and Bespak further collaboration to advance UK production of low carbon inhalers
Partnership increases industrial scale of low carbon pressurised metered dose inhalers (pMDIs), accelerating pharma’s transition to a more sustainable option.
-
NewsGSK grants rare disease firm Alfasigma rights to linerixibat for $690m
Licence agreement with the Italy-based pharma company to advance GSK’s ambitions in rare disease.